Derrell D. Porter, M.D. – Currently Chief Executive Officer of cTRL Therapeutics.  Prior to cTRL, Derrell was Chief Executive Officer and Founder of Cellevolve. Prior to that,  Dr. Porter was SVP and Head of Commercial at Atara Biotherapeutics, Inc. Prior to joining Atara, he was a Vice President with Gilead Sciences, where he was responsible for corporate strategy, long-term commercial planning, and global launch preparation for pipeline compounds in all of Gilead’s therapeutic areas – Oncology, HIV, Liver Diseases (HCV, HBV, and NASH), CV, and Inflammatory Disorders. With a successful biopharmaceutical career spanning 15+ years, Dr. Porter is a seasoned executive with experience running businesses in the US and Europe, corporate development, and global marketing, as well as management consulting, including AbbVie and Amgen. He began his career at McKinsey & Company in Los Angeles as part of the West Coast Health Care Practice. Dr. Porter holds an MD from the University of Pennsylvania, where he was a Twenty-First Century Scholar, an MBA from The Wharton School, and a bachelor’s degree in neuroscience from UCLA.

Doug Poling – Mr. Poling is a private investor with a financial and legal background. Previously, he served as Executive Vice President of AIG Financial Products Corp. with responsibility for three business units comprising energy and infrastructure principal investments, tax enhanced structured finance, and US corporate marketing. Before moving to the business side, Doug served as General Counsel and Chief Administrative Officer of AIG-FP for many years. He is a graduate of Tufts University (BA) and Yale Law School (JD).

Henry Cialone Ph.D. – Dr. Cialone is the President and CEO of Edison Welding Institute and has a record of creating new business opportunities through technological innovation. Prior to joining EWI in 2005, he was an executive at Battelle Memorial Institute, where he helped develop and manage a considerable alternative energy portfolio, ultimately leading the commercial energy business and serving on the governing board of the National Renewable Energy Laboratory. He received a Ph.D., MS, and BS in materials science and engineering from Brown University.

John Ryals Ph.D. – Co-Founder, CEO, and President at Paradigm Botanicals. Prior to Paradigm, Dr. Ryals served as Founder and Board Member at Metabolon. Dr. Ryals has 30 years of experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. Prior to founding Metabolon, Dr. Ryals was chief executive officer, president, and founder of Paradigm Genetics, Inc., a publicly-traded agricultural biotechnology company focused on industrializing the process of gene function discovery. He currently serves on the board of directors at AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a Bachelor of Arts in biology and chemistry from the University of North Texas and a Master of Science and Doctoral degrees in molecular biology from the University of Texas at Dallas.

Ronald Moss, M.D. – CMO at Adamis Pharmaceuticals Corporation. Prior to Adamis, Dr. Moss served as Chief Executive Officer of Ansun from October 2012 to February 2017. He previously served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. Dr. Moss has held various executive positions in the pharmaceutical industry for over 20 years and has played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. Dr. Moss has been involved in drug and vaccine product development in Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity in both large pharmaceutical and biotechnology companies. This has also included roles at Aventis, Immune Response, Merck, Telos, and Vical. He has also authored over 70 scientific publications. Prior to joining the industry, he received his M.D. degree from Chicago Medical School, completed a residency in pediatrics at SUNY Stony Brook, and completed a fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology.

Ross O. Youngs, Founder, and CEO – Ross has spent over 30 years inventing products, technologies, and processes for a variety of industries, and holds over 75 patents worldwide. He is driven to innovate by a focus on what is better, faster, and less expensive. Ross’ recent major innovations include an R&D 100 Award for collaboration on biopolymer technologies. In 2009, Biosortia was awarded a $6 million ARPA-E (U.S. Dept. of Energy R&D) grant for its algal harvesting technology, which helped lead to the development of Biosortia’s drug discovery platform.

In 1998, Ross was awarded the Ernst & Young Ohio Entrepreneur of the Year award. Additionally, the U.S. Small Business Administration honored him as their national “Business Person of the Year" in a presentation made by Vice President Al Gore.

slot gacor